Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock
07:18am, Monday, 23'rd Feb 2026
Novo Nordisk started the GLP-1 craze more than five years ago with injectable Ozempic. Five years later, the company's taken the lead again with Ozempic in a pill -- and almost the same stock price as
Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide Transcript
Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
06:43am, Monday, 23'rd Feb 2026
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy's launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's
Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.
06:32am, Monday, 23'rd Feb 2026
Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial.
These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More
05:58am, Monday, 23'rd Feb 2026
Nvidia shares tick up as investors await the chip maker's fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.
U.S. stock futures fell on Monday after closing higher on Friday. Futures of all the major benchmark indices were negative after the Supreme Court struck down federal tariffs imposed by President Dona
Novo Nordisk Stock Hits 52-Week Low After Weight-Loss Drug Falls Short Against Eli Lilly's
05:31am, Monday, 23'rd Feb 2026
Novo Nordisk stock sinks to a 52-week low after CagriSema missed its main goal in a late-stage obesity trial against Lilly's drug.
Novo Nordisk Shares Slide After Obesity Drug Misses Key Goal in Trial
05:13am, Monday, 23'rd Feb 2026
Shares fell sharply after the Danish drugmaker said its CagriSema experimental obesity drug failed to beat the weight loss delivered by Eli Lilly's Zepbound in a head-to-head clinical trial.
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
05:07am, Monday, 23'rd Feb 2026
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
04:53am, Monday, 23'rd Feb 2026
The drug, CagriSema, didn't achieve its primary endpoint of demonstrating non-inferiority on weight loss. In this article NVO
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
04:41am, Monday, 23'rd Feb 2026
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing
Bagsværd, Denmark, 23 February 2026 – Novo Nordisk today announced headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
09:42am, Sunday, 22'nd Feb 2026
Healthcare is an evergreen industry ripe for finding fantastic dividend-growth stocks. The Wegovy pill has breathed new life into Novo Nordisk.
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly
08:15pm, Friday, 20'th Feb 2026
Novo Nordisk's oral Wegovy seems to be expanding the weight loss market. However, it won't be enough to drive top-line growth this year.
Novo Nordisk's Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity
07:58am, Friday, 20'th Feb 2026
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch. Awareness and prescribing of the Wegovy pill for wei
